Mebendazole as Adjuvant Treatment for Colon Cancer
Overview
mebendazole treating colon cancer
Full Title of Study: “Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: December 2028
Detailed Description
mebendazole as adjuvant treatment for colon cancer
Interventions
- Drug: Folfox with avastin
- Folfox with avastin only
- Drug: Mebendazole
- Folfox with avastin with mebendazole
Arms, Groups and Cohorts
- Active Comparator: Folfox with avastin
- Folfox with avastin only
- Experimental: Mebendazole
- Folfox with avastin with mebendazole
Clinical Trial Outcome Measures
Primary Measures
- number of patients with tumour response
- Time Frame: 6 months
- number of patients with response
Participating in This Clinical Trial
Inclusion Criteria
- Colorectal cancer stage 4. Exclusion Criteria:
- Agranulocytosis – Pregnancy – Allergy to mebendazole.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Sherief Abd-Elsalam
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine – Tanta University
- Overall Official(s)
- Reham El-ghoneimy, Msc, Principal Investigator, Tanta University – Faculty of Pharmacy
- Sahar Hegazy, Prof, Principal Investigator, Tanta University – Faculty of Pharmacy
- Gamal el-azab, Prof, Study Director, Tanta University – Faculty of Pharmacy
- Fatma Zakaria, Prof, Study Chair, Clinical Oncology department. Tanta University.
- Overall Contact(s)
- Sherief Abd-Elsalam, ass. prof., 00201147773440, sheriefabdelsalam@yahoo.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.